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Abstract
Many recent publications highlight the large role of the pivotal eukaryotic nuclear export protein exportin-1 (XPO1)
in the oncogenesis of several malignancies, and there is emerging evidence that XPO1 inhibition is a key target
against cancer. The clinical validation of the pharmacological inhibition of XPO1 was recently achieved with the
development of the selective inhibitor of nuclear export compounds, displaying an interesting anti-tumor activity in
patients with massive pre-treated hematological malignancies. Recent reports have shown molecular alterations in the
gene encoding XPO1 and showed a mutation hotspot (E571K) in the following two hematological malignancies with
similar phenotypes and natural histories: primary mediastinal diffuse large B cell lymphoma and classical Hodgkin’s
lymphoma. Emerging evidence suggests that the mutant XPO1 E571K plays a role in carcinogenesis, and this variant is
quantifiable in tumor and plasma cell-free DNA of patients using highly sensitive molecular biology techniques, such as
digital PCR and next-generation sequencing. Therefore, it was proposed that the XPO1 E571K variant may serve as a
minimal residual disease tool in this setting. To clarify and summarize the recent findings on the role of XPO1 in B cell
hematological malignancies, we conducted a literature search to present the major publications establishing
the landscape of XPO1 molecular alterations, their impact on the XPO1 protein, their interest as biomarkers,
and investigations into the development of new XPO1-targeted therapies in B cell hematological malignancies.
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Background
Exportin-1, also called chromosome region maintenance
1 (CRM1/XPO1), is a pivotal eukaryotic nuclear export
protein that carries an extensive array of proteins from
the nucleus to the cytoplasm. XPO1 is a member of the
importin-β superfamily of karyopherins that mediates
the translocation of numerous RNAs and cellular regula-
tory proteins, including tumor suppressor proteins (TSPs),
such as p53, BRCA1, survivin, nucleophosmin, APC, and
FOXO. XPO1 hydrophobic groove binds to the leucine-
rich nuclear export signal (NES) domain of these “cargo”
proteins. XPO1 is overactive in many cancer [1–7], and
thus, XPO1 has been considered a potential anti-cancer
target for decades.
The clinical validation of the pharmacological inhibition
of XPO1 was recently achieved with the development
of the selective inhibitor of nuclear export (SINE)
compounds. SINEs are orally bioavailable small-
molecule inhibitors of XPO1-mediated nuclear protein
export [8–10].
Especially for hematological malignancies, many publi-
cations have highlighted the value and efficacy of several
SINE agents, all of which have an interesting anti-tumor
activity in patients with massive pre-treated hematological
malignancies [2, 8, 9, 11–15]. Currently, the dominant
SINE pharmacological agent, selinexor (KPT-330), is being
assessed in phase 1 and 2 clinical trials for various
cancers.
Furthermore, recent studies have focused on the
characterization of the molecular alterations in the gene
encoding XPO1 and showed a mutation hotspot
(E571K) in the following two hematological malignancies
with similar phenotypes and natural histories: primary
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mediastinal diffuse large B cell lymphoma (PMBL) and
classical Hodgkin’s lymphoma (cHL) [12, 16]. Missense
substitutions targeting XPO1 have also been previously
reported at a low frequency (<5%) in chronic lympho-
cytic leukemia (CLL) and esophageal squamous cell
carcinoma (ESCC), indicating that these mutations may
also play a role in other oncogenic processes [17–19].
We conducted a literature search to present the recent
major publications establishing the landscape of XPO1
molecular alterations, their impact on the XPO1 protein,
their interest as biomarkers, and investigations into the de-
velopment of new SINE therapies in B cell hematological
malignancies.
XPO1 gene and XPO1 protein
The XPO1 protein was first identified by a genetic
screening of Saccharomyces pombe and was recognized
as a nuclear component maintaining the higher order of
the chromosome structure [20]. Thereafter, XPO1 was
described as a ubiquitous nuclear export protein of the
karyopherin β family [21–23]. The human XPO1 gene is
located on chromosome 2p15, which is close to the
c-REL 2p16.1 locus, a locus well known to be gained
or amplified in PMBL, germinal B-cell-like (GCB) diffuse
large B cell lymphoma (DLBCL), and cHL.
The XPO1 protein 3D conformation and XPO1-
mediated nuclear export require the action of Ran
(Ras-related nuclear protein), a small G protein. A
RanGTP-RanGDP gradient is maintained across the
nuclear membrane due to the subcellular localization
of Ran regulators. Indeed, RanGDP is converted into
RanGTP through the action of RCC1 (regulator of
chromosome condensation 1), the Ran guanine nucleotide
exchange factor, which is tethered to the chromatin. In
contrast, RanGAP, the GTPase-activating protein, is cyto-
solic or bound to the outer cytoplasmic side of the nuclear
pore complex (NPC). RanGAP allows the dephosphoryla-
tion of RanGTP into RanGDP. As shown in Fig. 1,
RanGTP and cargos bind XPO1 in a cooperative manner,
forming stable ternary complexes that are exported
through the NPC. These complexes are disassembled in
the cytoplasm, cargos are released, and XPO1 is recycled
back to the nucleus for further rounds of export [24]. The
association–dissociation of XPO1-cargo complexes are,
thus, regulated by the direct binding of Ran in a
compartment-specific manner.
Structural analyses have shed light on the XPO1-
mediated export molecular mechanism. Crystal structures
of XPO1 bound to various NES-cargos and ternary
complexes of RanGTP/XPO1/cargos are available in the
Protein Data Bank [25]. Human XPO1 is a 120-kDa pro-
tein containing 21 consecutive tandem HEAT repeats
(H1–H21). Each HEAT repeat is formed by two antiparal-
lel α-helices A and B connected by loops of varying
lengths. The A helices align to form an outer convex
surface whereas the B helices form an inner concave
surface (Fig. 2) [26, 27]. The N-terminal HEAT and the C-
terminal HEAT are in close proximity, and XPO1 adopts a
ring or toroidal shape. The A helices of H11 and H12
form a hydrophobic groove that constitutes the NES-
binding site. The so-called leucine-rich NES motif, which
is present in XPO1 cargo proteins, is a short peptide
sequence of 10 ordered amino acid residues as follows:
Φ1X2-3Φ2X2-3-Φ3XΦ4, where Φ is either isoleucine,
leucine, methionine, phenylalanine, or valine, and X is any
other amino acids [28]. The hydrophobic side chain of
NES fits into five hydrophobic pockets along the NES-
binding groove [26, 27, 29]. The NES-binding groove of
the unliganded XPO1 adopts a closed conformation,
which is stabilized by the binding of the H9 loop to the
inner surface of H11 and H12. In this inhibited conform-
ation, the B-helix of H21 (called the C-helix) lies within
the central cavity with its C-terminus closed to the NES-
binding site [30]. The transition from this inactive state to
an active state is dependent on the binding of both
RanGTP and cargos. RanGTP associates with the inner
surface of XPO1 due to the movement of the H9 loop and
C-helix away from the inner surface [31]. In the cyto-
plasm, the ternary XPO1-cargo-RanGTP complexes are
dissociated. The binding of the Ran-binding domains
(RanBDs) present in RanGAP and the associated proteins
Ran-binding proteins 1 and 2 (RanBP1/2) induces a move-
ment of the H9 loop, driving the rotation and translation
of H11 and H12 and the release of cargos [31, 32]. Thus,
Fig. 1 Schematic representation of XPO1-mediated nuclear export.
RanGDP (D) is converted to RanGTP (T) through the action of RCC1
(the Ran guanine exchange factor). The export complex composed
of RanGTP, cargo (C), and XPO1 (X) proteins shuttles through the
nuclear pore complex (NPC) into the cytoplasm where RanGTP is
dephosphorylated by the action of RanGAP, the Ran GTPase-activating
protein. Cargo/XPO1 complexes are dissociated, and XPO1 shuttles
back to the nucleus for further rounds of nuclear export
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the affinity of XPO1 to its cargos is drastically reduced by
the site-directed mutagenesis of residues within the
NES-binding groove [28, 29]. Conversely, mutations
of the residues within the H9 loop or the deletion of
the C-helix increases the affinity of XPO1 to its cargos
[26, 32] and reduces the rate of cargo release [31].
Furthermore, García-Santisteban et al. recently described
a new cellular reporter to investigate XPO1 nuclear export
activity and the functional consequences of the highly re-
current cancer-related E571K mutation [33]. They showed
that this mutation increases the affinity of the XPO1
protein to NES sequences, which may shift the nucleocy-
toplasmic transportation and thus modify the cell equilib-
rium; thus, the mutant XPO1 E571K plays a role in
carcinogenesis.
XPO1 functions: nuclear export and mitosis control
As mentioned previously, NES sequences are diverse but
conform to the consensus sequence Φ1X2-3Φ2X2-3-
Φ3XΦ4. NESs were first described in the Rev protein of
HIV and the cyclic AMP-dependent protein kinase
inhibitor α (PKIα) [34, 35]. Currently, NESs have been
identified in more than 200 proteins with various
functions, such as cell cycle regulators, transcription fac-
tors, ribonucleoprotein complexes, translation factors,
and viral proteins. NESs are compiled in the following
comprehensive database: NESdb© [36, 37]. Among the
XPO1 cargos, several proteins such as TSPs (p53, p73,
FOXO1), growth regulators (RB, p21, CDC25, cyclin B1/
D1), and anti-apoptotic molecules (nucleophosmin, sur-
vivin) control essential physiological cellular processes.
Thus, correct XPO1 function is mandatory for normal
cell homeostasis. In turn, abnormalities in nuclear
export lead to diseases, including solid and hematologic
cancers. In eukaryotes, RNAs are exported from the
nucleus through the NPC. rRNAs (60S and 40S sub-
units), snRNAs, and a subset of miRNAs and mRNAs
are exported in an XPO1-dependent manner [38, 39].
RNA export requires specific adaptor proteins, such as
NDM3 [40].
Independently of its role in nuclear export, XPO1 is
involved in the maintenance of chromosome integrity
and the nucleation of microtubules at the kinetochore
[41, 42]. With its partners (RanBP2, RanGAP, and
RanGTP), XPO1 stabilizes the microtubules to the kinet-
ochores, thereby allowing proper chromosome segrega-
tion [43]. XPO1 is also present at the centrosomes
throughout the cell cycle. In complexes with RanGTP,
XPO1 recruits pericentrin, the major centrosomal scaf-
fold protein. Together with the microtubule nucleator
ϒ-TuRC complexes, XPO1 permits spindle microtubule
assembly [44]. Finally, RanGTP/XPO1 complexes bind
nucleophosmin and maintain the fidelity of centrosome
duplication [41, 44]. It is worth noting that the abnormal
functioning of the dual XPO1 functions (nuclear export
and mitosis regulation) could be highly deleterious
for cells initiating and/or maintaining transformation
processes.
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Fig. 2 3D-XPO1 conformations illustrating its interaction with RanGTP, RanGTP-SNUPN, LMB, and KPT-285. (a) Ring-shaped XPO1 is colored blue to
red in rainbow colors along the chain from the N-terminus to the C-terminus, showing the C-helix (red) autoinhibitory activity (PDB-ID 4FGV) [96],
(b) XPO1 complexed with snurportin 1 (SNUPN) (PDB-ID 3GB8) [27], (c) with RanGTP, in magenta (PDB-ID 5DIS) [97], or (d) with both proteins
(PDB-ID 3NC1) [28]. XPO1 inhibitors LMB (e) or KPT-185 (f) (both in red and arrowed) interacting with XPO1-RanGTP-RanBP1 (in gray) (PDB-ID,
4HAT [98], and 4GMX [9])
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Somatic mutations in CLL, PMBL, cHL, and other
B-cell malignancies
In a recent work based on NGS, the high prevalence of a
recurrent single nucleotide variant (SNV) (E571K) of
XPO1 in both PMBL and cHL was demonstrated for the
first time [12]. This mutation was observed in 25% of
cases and appeared to be a specific genetic feature of
these lymphomas as this mutation was observed at a
very low frequency or was absent from mediastinal
gray-zone lymphoma (MGZL) and GCB or activated
B cell-like (ABC) DLBCL cases. In another recent
study, recurrent XPO1 E571K mutations were found
in a large cohort of 94 patients with cHL using digital
PCR (Fig. 3) and NGS experiments [16]. This novel
information might provide new guidance on driver
events and tumorigenesis in cHL. In total, 24% of pa-
tients with cHL harbored the XPO1 E571K mutation.
In this study, including 94 patients with all stage of
cHL undergoing first-line treatment, the overall sur-
vival (OS) and progression-free survival (PFS) were
similar between the mutated and wild-type patients at
a median follow-up of 34.5 months. Furthermore, no
alternative XPO1 variants were detected by NGS on
cHL biopsies; however, to date, the impact of the
highly selected E571K mutation in the pathogenesis
of cHL remains unknown. Several proteins known to
play a major role in cHL oncogenesis, including
STAT1, FOXO1, or CIITA, have also been identified
as cargo proteins [45–47]. Whether the XPO1 muta-
tions impair the nucleus/cytoplasm transport of these
proteins remains to be confirmed.
There is clear evidence for a pathological imbrication
between PMBL and cHL, specifically the nodular scler-
osis subtype; whether both might derive from thymic B
cells is currently an area of discussion [48]. The fact that
the XPO1 E571K mutation is enhanced in both these
Fig. 3 Positron emission tomography (PET) and digital PCR plots from a biopsy specimen and plasma cell-free DNA from a classical Hodgkin
lymphoma patient with mediastinal involvement. Representative views of digital PCR (dPCR) plots (mutant samples) for XPO1 E571K quantification
in a tumor (VAF = 0.3%, left) and plasma cell-free DNA (cfDNA) (VAF = 0.15%, right) from a cHL patient at diagnosis by droplet dPCR (Biorad). Data
are displayed in a scatter plot based on the color of FAM and VIC events. Green, blue, orange, and black plots represent wild-type alleles, mutant
alleles, both alleles in the same droplet, or no amplifications, respectively. VAF, variant allele fraction
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subtypes emphasizes the hypothesis of a common origin
and a strong oncogenic role for this gene. The XPO1
mutation might serve as a distinctive genetic feature that
facilitates the differential diagnosis of PMBL from
DLBCL with mediastinal involvement, or MGZL, which
are genetically similar but clearly distinct in their natural
history and outcome [12, 49, 50].
Missense substitutions targeting XPO1 have also been
previously described at a low frequency (<5%) by NGS
experiments in CLL [17, 19] and ESCC [18]. Notably, in
a recent report, XPO1 mutations were also detected in
38 of 486 (7.8%) CLL patients, 74% of which were
E571K hotspot mutations [2]. An adverse prognostic im-
pact was demonstrated with these XPO1 mutations, but
the overall outcome was not poor in patients receiving
ibrutinib. Although the oncogenic process of mutations
in patients with CLL, PMBL, and cHL are unclear, the
recurrent nature of XPO1 mutations in these malignan-
cies strongly supports its involvement in the pathogen-
esis of the disease and suggests that these XPO1
mutations may occur in various oncogenic mechanisms.
Translocations and other mechanisms of
expression deregulation and copy gains
The XPO1 overexpression process in cancer cells is not
currently clearly known. Several mechanisms may be
involved, such as chromosomal translocations or gain of
copies of the XPO1 gene. It was recently demonstrated
that a cryptic XPO1-MLLT10 fusion detected by RNA-
sequencing is associated with the deregulation of the
HOXA gene locus expression [51]. HOXA-independent
activity of the XPO1-AF10 fusion protein could contribute
to leukemogenesis in T cell acute lymphoblastic leukemia
(T-ALL) via an abnormal transport of tumor suppressors
and growth-regulatory cellular factors and/or the domin-
ant negative inhibition of wild-type XPO1 [51].
Although the process of cyclin D1 nuclear import is
insufficiently characterized in mantle cell lymphoma
(MCL), the export of cyclin D1 complexes from the
nucleus into the cytoplasm is established to be XPO1-
dependent [52]. Indeed, the down-regulation of cyclin
D1, which was accompanied by a substantial decrease of
its target protein phospho-RB, was observed after a
SINE agent KPT-185 treatment in MCL cells [53]. The
t(11;14) nonrandom chromosomal translocation, leading
to cyclin D1 overexpression that is typical of MCL dis-
ease, may also explain the XPO1 overexpression in MCL
cells. This hypothesis must be confirmed in dedicated
studies to define the precise mechanisms of the deregu-
lation of XPO1.
It has also been reported that XPO1 and other nuclear
import receptors, such as importin-7, are regulated
positively by MYC and negatively by p53 [54], resulting
in the modulation of ribosomal biogenesis. MYC appears
to transcriptionally upregulate XPO1 as a part of a
wide-ranging transcriptional program that also includes
numerous ribosomal protein genes [55].
Recently, in 20 PMBL cases analyzed via CGH, a copy
number gain in the XPO1 locus was observed in eight
cases [12]. This rate was higher than that observed for
ABC DLBCL (8/70, 11%) but similar to that observed
for GCB DLBCL (21/74, 28%). A significant correlation
was observed between the XPO1 copy number and the
expression of the corresponding messenger RNA
(mRNA), suggesting a gene dosage effect (P = 0.00106,
Mann–Whitney test). Gains at the chromosome 2p16.1-
2p15 locus, which contains both the REL and XPO1 genes,
were commonly observed in GCB DLBCL, cHL, and
PMBL cases [56–58] and may be an important mechan-
ism of XPO1 overexpression in these hematological
malignancies.
XPO1 mutations to assess minimal residual
disease (MRD) in cHL and PMBL
The conveniences of using plasma cell-free DNA
(cfDNA) for tumor mutation detection include (i) nonin-
vasive acquisition, (ii) ability to be collected at any time
during the disease course, (iii) real-time detection and
follow-up of biomarker dynamics, and (iv) probably
fewer heterogeneity concerns than tumor tissue testing
[59]. Notably, the idea of a “liquid biopsy” was recently
featured for the first time in a series of DLBCL patients,
for whom high-throughput sequencing of a panel of
target genes was implemented with an outstanding de-
tection of somatic variants both in the tumor and the
plasma [60]. Undeniably, the testing of mutations in the
cfDNA has been widely characterized in many cancer
types and could potentially serve as a biomarker tool for
MRD, revealing treatment success or disease relapse
before the clinico-radiological symptoms [61–64].
In contrast, Lymphosight® technology [65], which is
based on the quantification of clonotypic immunoglobulin
rearrangements, can be used more extensively to predict
relapse in DLBCL patients [66], but a VDJ rearrangement
is not measurable in all patients (immunoglobulin-nega-
tive phenotype of PMBL [67]), and the technology is not
suitable for tailoring a targeted therapy. Furthermore, a re-
cent proof-of-concept report exposed, for the first time,
that the detection and measurement of recurrent somatic
mutations in the plasma cfDNA of patients with DLBCL
by digital PCR is possible, easy, and reproducible [68].
cfDNA testing by digital PCR (dPCR) is emerging as an
appropriate and helpful molecular tool for the manage-
ment of DLBCL along with NGS methods.
Finally, a recent retrospective study, including 94
all-stage cHL patients undergoing a first-line therapy,
demonstrated that the highly recurrent XPO1 E571K mu-
tation is present in one-quarter of classical Hodgkin’s
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lymphoma patients [16]. Among these 94 patients, 50 had
serial EDTA plasma samples obtained from blood collec-
tion concomitant with the diagnostic biopsy and at the
end of chemotherapy/radiotherapy treatment. Patients
with a detectable XPO1 mutation in plasma cfDNA by
digital PCR at the end of treatment exhibited a tendency
toward shorter progression-free survival compared to pa-
tients with undetectable mutations. These results advocate
that the clearance of the XPO1mutation in plasma cfDNA
during and at the end of treatment may serve as a new
prognostic marker for patients with detectable mutations.
A study with a larger prospective cohort is needed to draw
precise conclusions and determine whether this mutation
monitoring adds new applicable value compared to posi-
tron emission tomography (PET) and whether this E571K
variant can be targeted by SINE compounds for the treat-
ment of cHL.
XPO1 dysfunction as a diagnostic and/or
prognostic marker
XPO1 overexpression positively correlated with a larger
tumor size in ESCC [18]. Moreover, the XPO1-mutated
tumor also showed upregulated protein levels compared
with the matched adjacent normal esophageal epithelium,
indicating a gain-of-function phenotype. In hematological
malignancies, high levels of XPO1 are associated with
shorter survival and are a poor prognostic factor in acute
myeloid leukemia (AML) [69]. In this pathology, high
XPO1 levels correlate with low MDM2 and high p53
levels.
Multiple myeloma (MM) cells have a higher XPO1
expression than bone marrow normal plasma cells and
cells from monoclonal gammopathy of unknown signifi-
cance (MGUS) patients [70].
An altered subcellular localization of XPO1 in MCL
cell lines and primary cells and the knockdown of XPO1
gene expression resulted in the inhibition of MCL cell
growth [71]. XPO1 is overexpressed in MCL cells and
can regulate MCL cell proliferation, cell cycle progres-
sion, DNA damage response, and chromosomal stability,
making it a promising therapeutic target for MCL man-
agement [71]. Another study confirmed these results
and revealed that XPO1 overexpression has a negative
prognostic impact on MCL overall disease survival [72].
This work highlighted that the induction of p53 by SINE
agents could potently induce cell death in MCL, includ-
ing those with high levels of XPO1. The unfavorable
prognostic impact of high levels of XPO1 expression
was also demonstrated in an impressive study in MM
[73]. In this work, high XPO1 expression in MM patient
cells was associated with lytic bone disease and a shorter
survival, and bortezomib-resistant patient MM cells
expressed higher XPO1 levels. The authors showed that
SINE treatment induced potent and rapid apoptosis of
MM cells in vitro and in vivo and further directly
decreased bone resorption. These results are interesting
additional data supporting a pathogenic role of XPO1 in
hematological malignancies and providing the pre-
clinical rational for the ongoing clinical development of
selinexor.
Nevertheless, cHL patients with tumors harboring the
E571K XPO1 mutation did not have a shorter PFS or OS
than cLH patients with a wild-type XPO1 gene [16]. By
contrast the E571K XPO1 mutation may have an un-
favorable prognostic relevance for PMBL [12], which
is in accordance with the observations reported for
CLL [17].
Targeting XPO1 by SINE compounds
Leptomycin B (LMB), an anti-fungal antibiotic produced
by Streptomyces, was the first described XPO1 inhibitor
(Fig. 4). In their seminal report, Kudo and colleagues
showed that LMB binds XPO1 at a conserved cysteine
residue (position 528 in the human protein, C528) [74].
The alkylation of this cysteine residue, within the hydro-
phobic groove of XPO1, by LBM disrupts XPO1/cargo in-
teractions and prevents the binding of RanGTP. Thus,
LMB blocks nuclear export. Interestingly, the substitution
C528S has no impact on XPO1 function, but cells carrying
the C528S mutation are completely resistant to LMB. Al-
though highly potent, even at nano-molar concentrations,
LMB cannot be used in the clinic because of its high tox-
icity [75]. Recently, using computational methods, several
XPO1 inhibitors, called selective inhibitors of nuclear ex-
port (SINE), have been developed by Karyopharm Thera-
peutics (e.g., KPT-185 and KPT-330, also known as
selinexor, Fig. 4). SINEs inhibit the formation of XPO1/
cargo complexes. Moreover, the crystal structures of
SINEs showed that they bind covalently to C528, such as
LMB [8, 9]. A homozygous mutation in the cysteine resi-
due (C528S), using the CRISPR/Cas9 technology in the
Jurkat T-ALL cell line, confers cell resistance to selinexor
[76]. This result validates the specificity of the SINE to its
target, XPO1. SINEs display anti-proliferative and pro-
apoptotic activities in various hematological malignancies
in both in vivo and in vitro settings, including cell lines
and primary cells [15]. The main results of published pre-
clinical studies are presented in Table 1. SINEs inhibit the
XPO1 nuclear export function and restore the nuclear
localization of TSPs and cell cycle proteins, thus restoring
their functions. Importantly, SINEs target tumor cells but
not normal hematopoietic cells [8, 9]. SINEs can also in-
directly restore TSP and cell cycle regulator functions. In
addition to the high XPO1 expression found in AML cells,
the NPM1 gene encoding nucleophosmin 1 is mutated in
up to 35% of cases [77]. These mutations cause increased
XPO1 binding and the mislocalization of nucleophosmin
1 in the cytoplasm [78]. KPT-185 restores the nuclear
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localization of nucleophosmin 1, resulting in cell cycle ar-
rest and AML blast differentiation [79].th=tlb=
Pre-clinical studies in CLL cells with a mutated XPO1
gene have not been reported thus far to our knowledge.
However, in PMBCL and LH cell lines, KPT-185 inhibits
cell proliferation and induces apoptosis, regardless of an
amplified or mutated XPO1 gene status [12, 16].
Moreover, SINEs synergize with drugs used clinically
to bypass the resistance that often occurs after treat-
ment. In AML, topoisomerase (Topo) 2α (an XPO1
cargo) is aberrantly localized in the cytoplasm, leading
to resistance to Topo2 inhibitors. Ranganathan and col-
leagues recently reported the synergistic activity of seli-
nexor with Topo2 inhibitors (idarubicin, daunorubicin)
in AML cell lines, primary AML blasts, and a murine
xenograft model [80]. Mechanistically, selinexor restores
the nuclear localization of Topo2, downregulates genes
in the DNA damage response pathway and impairs hom-
ologous recombination for DNA repair. In AML, a high
level of XPO1 correlates with a high level of p53 and a
low level of mouse double minute 2 (MDM2, the nega-
tive regulator of p53). KPT-185 and Nutlin-3a, inhibitors
of MDM2, display synergistic activity on apoptosis in-
duction both in AML cells lines and primary cells [69].
Indeed, the nuclear accumulation of p53 induced by
XPO1 inhibition is reinforced by the lack of p53 degrad-
ation resulting from MDM2 inhibition. Decitabine, an
inhibitor of DNA methyltransferase that allows the re-
expression of genes silenced during myeloid differenti-
ation, appears to be efficient for some AML patients
[81]. The pretreatment or priming of AML blasts with
decitabine followed by selinexor enhances the induction
of apoptosis in AML cell lines and primary AML blasts
[82]. These effects are mediated by the re-expression of
p21 and FOXO3A, which are XPO1 cargos that are
silenced by the DNA methylation. In vivo, in a mouse
model of AML, a selinexor/decitabine combination
shows enhanced anti-leukemia activity.
CLL cells exhibit a constitutive activation of the BCR
signaling pathway. Ibrutinib, which inhibits BTK (Bruton
tyrosine kinase) expressed in CLL, is an effective therapy.
However, acquired resistance to ibrutinib is frequent,
partly due to a mutation in the BTK gene (C481S). The
dual targeting of XPO1 by selinexor and BTK by ibrutinib
elicits a synergistic effect both in vitro in primary cells and
in vivo in the Eμ-TCL1 mouse model of CLL [83]. Import-
antly, the selinexor/ibrutinib combination bypasses the
resistance due to the C481S BTK mutation.
The combination of an XPO1 inhibitor and liposomal
doxorubicin appears highly effective in in vitro resistant
MM models, xenograft studies, and ex vivo samples
from patients with relapsed/refractory myeloma. In pre-
clinical models, the anti-lymphoma activity of selinexor
is enhanced through a combination with dexamethasone
and everolimus, which target both NF-κB and mTOR
[14]. A synergistic effect has been demonstrated with
proteasome inhibitors (PIs), such as carfilzomib and
bortezomib [84] and selinexor, the latter of which over-
comes PI drug resistance in MM. This synergistic effect
is mediated by blocking the phosphorylation of the IκB-
α and the NF-κB p65 subunits, protecting IκB-α from
proteasome degradation [13].
Although selinexor has shown its efficacy in phase I/II
clinical trials (see below), its toxicity limits its adminis-
tration. A new generation of SINE compounds has been
designed by Karyopharm Therapeutics and assayed for
efficacy in CLL and AML [85]. KPT-8602 acts similarly
to selinexor; it inhibits XPO1/cargo interactions, induces
apoptosis, and inhibits proliferation of primary CLL
cells, AML cell lines, and AML blasts. In vivo, in mouse
models of AML and CLL, KPT-8602 prolongs survival.
More importantly, compared to selinexor, KPT-8602
Fig. 4 Chemical structures of leptomycin B and two SINE compounds. Chemical structures have been obtained from [99]
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Table 1 Pre-clinical in vitro and in vivo studies of KPT compounds on hematological malignancies
Disease XPO1 gene and protein SINE Effects Reference
AML KPT-185 Induces apoptosis
Promotes cell cycle arrest and inhibits proliferation
Decreases XPO1 level and restores nuclear export
Downregulates FLT3 and KIT oncogenes expression
[79]
KPT-276 Increases survival of FLT3-ITD+-MV4.11 mice
CLL High XPO1 expression KPT-185 Inhibits nuclear export
Induces apoptosis of tumor cells not of normal B cells
Targets the IκB pathway
Antagonizes microenvironment stimuli (TNF, IL6, IL4)
Inhibits tumor growth in vivo (Eμ-TCL1-SCID model)
[9]
T-ALL KPT-185 Induce apoptosis in vitro and in vivo [8]
KPT-330 Promote cell cycle arrest in G1
Inhibit tumor growth in vivo
AML High XPO1 expression KPT-185 Inhibits nuclear export
Induces a p53-dependent cell apoptosis
Inhibits cell proliferation in a p53-idependent manner
AML KPT-330 Inhibits XPO1/cargo interactions and nuclear export [8, 100]
KPT-251 Induces apoptosis
Promotes cell cycle arrest in G1
Inhibits tumor growth in vivo
Inhibits tumor growth in vivo
MCL High XPO1 expression KPT-185 Blocks nuclear export [71]
KPT-276 Induces apoptosis in a p53-independent manner
Has no effect on cell cycle
Inactivates the NF-κB pathway
Inhibits tumor growth in vivo
MM High XPO1 expression KPT-276 Induces cell apoptosis in vitro and in vivo
Targets c-Myc, CDC25A, and BRD4
Induces cell cycle arrest in G1
[70]
MM High XPO1 expression KPT-185 Inhibit nuclear export [73]
KPT-330 Induce apoposis and alleviate CAM-DR
Promote cell cycle arrest in G1
Target c-Myc, MCL1, and NF-κB pathway
Show a strong anti-myeloma activity in vivo,
impair osteoclastogenesis and bone resorption
NHL KPT-185 Inhibits cell growth
Induces apoptosis
Restores the nuclear localization of TSPs and their function
Shows anti-tumor activity in vivo
[101]
Ph + ALL High XPO1 expression KPT-330 Induces apoptosis both p53-dependent and -independent
Decreases clonogenic potential
Increases survival of BCR-ABL1 mice
Alters the localization of hnRNP A1 and SET
Reactivates the TSP PP2A
[102]
CLL KPT-330 Suppresses effectors of BCR signaling in vitro and in vivo
via BTK depletion
Prevents CLL cells migration
[103]
HL Mutation E571K
XPO1 amplification
KPT-185 Inhibits cell line proliferation and induces apoptosis
whatever XPO1 status
[16]
PMBL Mutation E571K
XPO1 amplification
KPT-185 Inhibits cell line proliferation and induces apoptosis
whatever XPO1 status
[12]
AML/CLL/DLBCL KPT-8602 Inhibits XPO1/cargo interactions and nuclear export
Induces apoptosis of primary CLL cells
Inhibits proliferation of DLBCL cell lines (ABC and GC subtypes)
Prolongs the survival of Eμ-TCL1 mice
Acts in synergy with ibrutinib in vivo
Inhibits proliferation and induces apoptosis of AML cell lines
and primary blasts
Is efficient in a mouse model of AML
[85]
Abbreviations: ABC activated B cell like, ALL acute lymphoid leukemia, AML acute myeloid leukemia, BCR B cell receptor, BRD4 bromodomain-containing protein
4, BTK Bruton tyrosine kinase, CAM-DR cell adhesion-mediated drug resistance, CDC25A cell division cycle 25 homolog A, CLL chronic lymphoid leukemia, DLBCL
diffuse large B cell lymphoma, FLT3 FMS-like tyrosine kinase, GC germinal center, IL interleukin, ITD internal tandem duplication, HL Hodgkin lymphoma, hnRNP
heterogeneous nuclear ribonucleoprotein, MCL mantle cell lymphoma, MDM2 human homolog of mouse double minute 2, MM multiple myeloma, NHL
non-Hodgkin lymphoma, PP2A protein phosphatase 2A, PMBL primary mediastinal B cell lymphoma, TNF tumor necrosis factor, TSP tumor suppressor protein
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appears to be less toxic because it has a reduced capacity
to cross the blood–brain barrier and does not accumu-
late in the blood even after repetitive injections.
Resistance to therapy and relapse occur because of the
inability of the currently used drugs to target the cancer-
initiating cells (CICs) or leukemia-initiating cells (LICs). A
CIC/LIC is defined as a cell, within the tumor population,
that is able to self-renew, differentiate, and reproduce a
tumor. Such an LIC has been described in AML [86, 87].
Selinexor appears to be active against primary AML cells,
including LICs engrafted into immunodeficient mice.
Moreover, selinexor shows limited toxicity against normal
hematopoietic stem cells and progenitors [88].
The inhibition of RNA export and the impairment of
ribosome biogenesis induce the death of MCL and MM.
In MCL cells, KPT-185 induces a down-regulation of
proliferation-related genes regardless of the status of p53
and, in turn, the inhibition of the cell cycle. Moreover,
KPT-185 downregulates the expression of ribosomal pro-
teins (from both the large 60S and the small 40S sub-
units). This affects heat shock factors, protein synthesis,
and energy metabolism that are important for tumor cell
proliferation and survival [53]. In MM cells, selinexor tar-
gets the RPL11 and RPL5 ribosomal proteins, decreases
the 40S, 60S, and 80S ribosomal fractions, and disrupts
the ribosomal function and translational machinery. This
induced ribosomal stress leads to MM cell death [53].
XPO1 inhibition also represents a new therapeutic strat-
egy for overcoming resistance to platinum-mediated apop-
tosis through both p53-dependent and p53-independent
pathways [89]. The combination synergistically induced
Topo 2α-mediated DNA damage and subsequent
apoptosis. In solid tumor models, it has been demon-
strated that selinexor acts synergistically with gemcitabine
to promote apoptosis and reduce survival [90] and can en-
hance radiotherapy effects, providing a rational for such a
combination in B cell malignancies [91], including non-
Hodgkin lymphoma (NHL) and cHL.
Finally, in a model of synergistic colon/melanoma
cancer, a combination of selinexor + programmed cell
death 1 (PD-1 or PD-L1) blockade exerts considerable
anti-tumor activity and shows significant immunomodula-
tory activity, inducing changes in the frequency and pheno-
type of immune cell populations, most notably in NK cells
and activated T cells. These results support the future
clinical evaluation of the combination of selinexor + PD-1/
PD-L1 blockade, a strategy especially relevant in cHL [92].
Importantly, in vitro and in vivo experiments are providing
the rational for the ongoing and future clinical trials based
on the combination of XPO1 inhibitors and approved
drugs (Table 2).
These data reinforce the concept of XPO1 as an anti-
cancer target and SINEs as efficient anti-XPO1 drugs in
human hematological malignancies.
Clinical experience in B-cell malignancies
Giving the pleiotropic and crucial role of XPO1 and the
fact that the overexpression of XPO1 has been associated
with resistance and aggressiveness in multiple tumor
types, several clinical trials using drugs targeting XPO1
are currently ongoing in the field of hematological malig-
nancies and solid tumors. The ongoing or terminated clin-
ical trials testing the SINE selinexor compound in
lymphoid malignancies are summarized in Table 2.
Table 2 Clinical trials in lymphoid malignancies testing selinexor as single agent or in combination
NCT Phase Lymphoid malignancy Therapeutic strategy/combination Estimated enrollment Status
NCT01607892 I Hematologic malignancies Selinexor 285 Not recruiting
NCT02138786 II Richter’s transformation lymphoma Selinexor 26 Terminated
NCT02186834 I/II MM Selinexor, liposomal doxorubicin,
dexamethasone
47 Recruiting
NCT02199665 I MM Selinexor, carfilzomib, dexamethasone 48 Recruiting
NCT02227251 II R/R DLBCL Selinexor 200 Recruiting
NCT02303392 I CLL, lymphoma Selinexor, ibrutinib 92 Recruiting
NCT02314247 II TCL Selinexor 16 Terminated
NCT02336815 II MM Selinexor, dexamethasone 210 Recruiting
NCT02343042 I/II MM Selinexor, dexamethasone, bortezomib,
pomalidomide
201 Recruiting
NCT02389543 I/II MM Selinexor, lenalidomide, dexamethasone 34 Withdrawn
NCT02471911 I R/R aggressive B cell lymphoma Selinexor, rituximab, etoposide, carboplatin,
ifosfamide, dexamethasone
18 Recruiting
NCT02741388 I R/R B cell lymphoma Selinexor, rituximab, dexamethasone,
oxaliplatin, cisplatin, cytarabine, gemcitabine
60 Recruiting
Data are from ClinicalTrials.gov [104]
Abbreviations: CLL chronic lymphoid leukemia, MM multiple myeloma, R/R refractory/relapse, TCL T-cell lymphoid leukemia
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Consolidated clinical results in CLL, MM, and NHL are
still limited.
In a phase 1 dose-escalation study of selinexor in
patients with heavily pre-treated NHL, among the 43
evaluable patients, an overall response rate of 28% was
observed with a complete response rate of 5%. In the
DLBCL cohort of 39 evaluable patients, the disease
control rate was 51%, with overall response rate of 31%.
Interestingly in DLBCL patients with MYC/BCL2 trans-
locations, three of the four patients showed an objective
response [93].
The toxicity profile of selinexor used as a single agent
is currently well-known. In a phase 1 trial involving 189
patients with advanced solid tumors receiving selinexor,
the most common treatment-related adverse events
included fatigue (70%), nausea (70%), anorexia (66%),
and vomiting (49%), which were generally grades 1 or 2.
The most commonly reported grade 3 or 4 toxicities
were thrombocytopenia (16%), fatigue (15%), and hypo-
natremia (13%). Clinically significant major organ or cu-
mulative toxicities were rare. The maximum-tolerated
dose was set at 65 mg/m2 using a twice-a-week (days 1
and 3) dosing schedule [11]. Selinexor was significantly
better tolerated when administered as a flat dose on an
intermittent schedule. Pharmacokinetics analysis of seli-
nexor revealed an increase (approximately 15 to 20%) in
drug exposure when taken with food [94]. A phase I trial
evaluated the combination of selinexor with fludarabine
and cytarabine in pediatric R/R acute leukemia. The
most common grade 3 non-hematologic toxicity was
asymptomatic hyponatremia. Two patients who were
treated at 70 mg/m2 experienced reversible cerebellar
toxicity, thereby defining the dose-limiting toxicity [95].
Interestingly, the new SINE compound KPT-8602
shows similar in vitro potency compared with seli-
nexor but lower central nervous system penetration,
which resulted in enhanced tolerability, even when
dosed daily, and improved survival in CLL and AML
murine models [80, 82].
Conclusion
XPO1 represents an exciting field located at the intersec-
tion between pathophysiology, diagnosis, and treatment of
B cell malignancies. Many crucial points and burning
questions need to be addressed. At the biological level, the
respective role of XPO1 in distinct B/T cell malignancies
is still largely unknown, and an accurate view of the cargo
molecules (including proteins and RNAs) is still lacking.
At the genetic level, the highly selected recurrent E571K
mutation does not appear to impact the activity of SINE
compounds, but its biological relevance, especially in cHL
and PMBL, is still undetermined. Interestingly, this
hot spot may be used as a simple MRD marker to
complement PET scan imaging in these diseases. Fi-
nally, from a clinical point of view, blocking XPO1
activity represents a promising strategy in lymphoid
malignancies and has synergistic effects with several
drugs, including anthracyclines, gemcitabine, mTOR
inhibitors, ibrutinib, immune check-points inhibitors
or radiotherapy.
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